Our results showing a significant improvement in cardiovascular outcomes regardless of the underlying diabetes are of great importance and should motivate future randomized trials to further assess the cardiovascular efficacy of GLP‐1 agonists in patients with cardiovascular conditions without diabetes. Here, GLP1R is linked to diabetes mellitus.